Spiegel R. — Psychopharmacology: an introduction :: Электронная библиотека попечительского совета мехмата МГУ

Главная Ex Libris Книги Журналы Статьи Серии Каталог Wanted Загрузка ХудЛит Справка Поиск по индексам Поиск Форум

Авторизация

Поиск по указателям

Spiegel R. — Psychopharmacology: an introduction

Обсудите книгу на научном форуме

Нашли опечатку?
Выделите ее мышкой и нажмите Ctrl+Enter

Название: Psychopharmacology: an introduction

Автор: Spiegel R.

Аннотация:

Describes the latest advances in psychopharmacology - one of the most rapidly developing fields in modern science. This latest edition has been updated to cover new developments in drug therapy and research including newly introduced antipsychotics, antidepressants and antidementia drugs. Sections on the treatment of depression and dementia have been revised to include new developments in treatment strategies. It will be welcomed for its essentially clinical and psychological approach to modern pharmaceuticals, their therapeutic uses and limitations, adverse reactions and future directions for research.

Язык:

Рубрика: Медицина и здравоохранение/

Статус предметного указателя: Готов указатель с номерами страниц

ed2k: ed2k stats

Издание: fouth edition

Год издания: 2003

Количество страниц: 400

Добавлена в каталог: 11.12.2005

Операции: Положить на полку | Скопировать ссылку для форума | Скопировать ID

Предметный указатель

Medical model, the, criticism of      320—321
Medical research, basic principles for      326—329
Medication, psychotropic, effects on healthy subjects      57—97
Medicine, in Middle Ages      31
Megaphen $\textregistered$       5
Melancholy      29
Mellaril $\textregistered$       5
Memory      235 237
Memory and learning      67—68
Memory and learning, processes of      67
Memory and learning, state-dependent      68
Memory and learning, time criticality of tests for      67—6Я
Memory, deterioration      237
Memory, improvement      26 237
Mental disease, prevalence of      148
Mental disorders, treatment by Pharmaceuticals      261—300
Mental functions, determination of      97
Mental illness in ancient Arabia      31
Mental illness in ancient Egypt      29—30
Mental illness in ancient Greece      30—31
Mental illness in Medieval Europe      31—32
Mental illness in the Bible      30
Mental illness, medical model of      32
Mental retardation      29
Mephenesine      44 46
Meprobamate      44—48 (46) 95
Meprobamate, Alzheimer patients, and      96
Mesoridazine      5
Meta-chlorophenyl-piperazme (MCPP)      160 218
Metabolism      see ADME
Metabolite      105
Methamphetamine      25
Methidate $\textregistered$       25
Methyl-chlorophenylpiperazine challenge      187—188
Methylin $\textregistered$       25
Methylphenidate      25
Methylphenidate and ADHD      296—297
Methylphenidate and P300 complex      94
Methylphenidate, brain metabolism and      217
Methylphenidate, stimulant effect of      86—87 95 247—248 250
Methylphenidate, studies/trials of      250—251
Mianserin      11 82
Mianserin, effects of      79—81 (80) 95
Mice      114
Mice, CRF-over expressing      141—142
Mice, effects of reserpine/imipramine on      118
Mice, genetically modified      143
Mice, knockout strains      139
Mice, knockout strains, studies on      124
Mice, laboratory tests, and      132 134—137
Mice, neurokinin-1 receptor knockout      142
Mice, PPI deficit strain      131
Mice, tigmotaxis in      130
Midazolam      19 161
Mini-International Neuropsychiatric Interview (MINI)      197
Mini-Mental State Evaluation (MMSE)      203 239—240 254
Mirtazapine      11 126 236 238 276 293
Mirtazapine, action spectra of      12
Mirtazapine, side effects of      14
MMSE      see Mini-Mental State Evaluation
Moban $\textregistered$       5
Moclobemide      11
Moclobemide and depression      126 279
Moclobemide, action spectra of      12
Moclobemide, effects of      79—82 (80)
Moclobemide, phobia trials of      294
Moclobemide, side effects of      14—15
Modafinil      25 85 87
Modelling, analytical      313—315 317
modification of      8
Mogadon $\textregistered$       19
Molindone      5
Molipasin $\textregistered$       11
Monoamine      Plate 6.1
Monoamine oxidase (MAO)      226 286
Monoamine oxidase (MAO), inhibitors (MAOIs)      41 47 54 119 126 133 236
Monoamine oxidase (MAO), inhibitors (MAOIs), and catecholamines      119
Monoamine oxidase (MAO), inhibitors (MAOIs), and depression      120
Monoamine oxidase (MAO), inhibitors (MAOIs), and serotonin      119
Montgomery-Asberg Depression Rating Scale (MADRS)      198
Mood disorders      234
Mood stabilizers      1—3 (2) 15—17 149 263
Mood stabilizers, clinical actions and uses      15—16
Mood stabilizers, effects of      240—241
Mood stabilizers, side effects      17
Morphine      28 35—36 59—60 162
Moscop      36
Motivation      58
Motor disorders, extrapyramidal      8
Motor performance and executive function      70
Motor performance and executive function, tests for      71
Motor symptoms, exirapyramidal      51
MRI      see magnetic resonance imaging
MRS      see magnetic resonance spectroscopy
MTD      see maximum tolerated dose
Mtmtiragora      34
Multimodal treatment study (MTA), the      297
Multimodal treatment study (MTA), the, children with ADHD      250—252
Multiple sclerosis, and MRI      213
Muscle pain      21
Muscle relaxants      20 44 46
Muscle tension      20
Myocardial activity      7
Myorelaxants      3 23 242
N-methyl-D-aspartate (NMDA)      117
Naproxen      257
Narcolepsy      2 24—25 36
Narcoses, induction of      34
Narcotics      2 3 35
Naringine      160
Nasal congestion      14
National Institute for Clinical Excellence (NICE)      303—304
National Institute of Mental Health (NIMH)      250
Nausea      14 17 21 23 25 88 239 256 276 307
Navane $\textregistered$       5
Neck, stiff      8
Nefazodone      11 160—161
Nefazodone and depression      276 288
Nefazodone and GAD      293
Nefazodone as antidepressant      238
Nefazodone, action spectra of      12
Nefazodone, effects of      80—82
Nefazodone, side effects of      14
Nervous system, the      100—101
Neuleptil $\textregistered$       5
Neurocil $\textregistered$       5
Neurodevelopmental models      132
Neurodevelopmental models, toxic agents, and      132
Neuroendocrinology      162
Neuroimaging      207—226
Neuroimaging, functional imaging, types of      214—226
Neuroimaging, functional imaging, types of, drug disposition      224—225
Neuroimaging, functional imaging, types of, drug disposition, assessment by MRS      225—226
Neuroimaging, functional imaging, types of, measurement of brain metabolism      215—218
Neuroimaging, functional imaging, types of, measurement of cerebral blood flow and volume      218—221
Neuroimaging, functional imaging, types of, receptor occupancy theory      221—224
Neuroimaging, techniques      208—214
Neuroimaging, techniques, magnetic resonance      211—214
Neuroimaging, techniques, radioisotopes      208—211
Neurokinin receptor antagonists      121—122
Neurokinin-1 (NK1)      121
Neurokinin-1 (NK1) and depression      121—122
Neurokinins      142
Neuroleptic malignant syndrome (NMS)      8
Neuroleptics      1 3 23 37 42—44 50—52 55 79 96 161 319
Neuroleptics and tardive dyskinesias      7—9 (8)
Neurons      101—102
Neurons, structure of      101
Neurontin $\textregistered$       16
Neuropeptide Y      110

Neurophysiological approaches      93—94
Neurophysiology, parameters of      70—76
Neuroses      18 40 319—320
Neurotransmitters      105 110 113 125 324
Neurotransmitters and depressive symptoms      118
Neurotransmitters, chemical structures of      111
Neutropenia      14
Nialamide      12
nice      see National Institute for Clinical Excellence
Nicotine      1—2 219
Nightmares      25
NiMH      see National Institute of Mental Health
Nimodipine      16 279
Nitrados $\textregistered$       19
Nitrazepam      19 242
Nitrous oxide      218
NMS      see neuroleptic malignant syndrome
Nocebo effect      185
Noctamid $\textregistered$       19
Non-inferiority trial      176
Nootropics      2 25—26 189
Nootropics, experiments on      87—89
Nootropics, experiments on, behavioral effects      88—89
Nootropics, experiments on, neurophysiology      89
Nootropics, experiments on, subjective effects      87 88
Nootropics, on healthy subjects      87
Nootropics, well known      26
Nootropil $\textregistered$       26
Noradrenaline (NA)      110—111 113 115 126—127 292
Noradrenaline (NA), augmented by imipramtne      118
Norepinephrine      52—53 172 Plate
Norepinephrine, reuptake blocked      53
Normison $\textregistered$       19
Nortriptyline      10—11 13 236 238—240
Nortriptyline, action spectra of      12
Nosology      319—320
Noveril $\textregistered$       11 83
Noxiptiline      11
Nozinan $\textregistered$       5
Nuclear magnetic resonance (NMR)      211—212 225
Objectives, experimental, drug-oriented      57
Objectives, experimental, methodology-oriented      58
Objectives, experimental, practice-oriented      58
Objectives, experimental, theory-oriented      58
Objectives, experimental, understanding clinical drug effects      58
Obsessive-compulsive disorder      23 166 169 246 291—292
Obsessive-compulsive disorder, scales for      201
Olanzapine      5—7 16 161
Olanzapine and bipolar disorder      279
Olanzapine, action spectra of      12
Olanzapine, discovery/introduction of      51—52 55
Olanzapine, effects of      77—78 89 230—233
Olanzapine, pharmacology of      117 127
Olanzapine, studies/trials of      177 181 264
Omca $\textregistered$       5
Open-field test      135
Open-label comparative trials      181
Opiates      22 36 291
Opipramol      11 123
Opipramol, action spectra of      12
Opium      27—30 34—36
Opium, addiction      34—35
Opium, uses of      28
Orap $\textregistered$       5
Oswald, I.      73
Oxazepam      19 85 242
Oxiracetam      188
Oxygen $(^{15}O)$ , in functional imaging      209 218
Oxyhemoglobin      213
Palpitations      13 267 292
Panic disorder      19 23 169 242 246 291—292 296
Panic Disorder Severity Scale (PDSS)      200
PANSS      see Positive and Negative Symptom Scale
Papaver somniferwn      28
Paracelsus      28 31
Paradoxical reactions      20
Paraldehyde      35—36 59
Paraldehyde, paralysing action of      60
Paranoia      4 263
Paranoia in old age      3
Parkinson's disease      54 114 125—126 220 313—314
Parkinsonism      7 8 38
Paroxetine      11 161
Paroxetine and depression      276
Paroxetine and GAD      292—293
Paroxetine and social phobia      23 294
Paroxetine, action spectra of      12
Paroxetine, brain metabolism and      217
Paroxetine, discovery/introduction of      53
Paroxetine, effects of      79 81—82
Paroxetine, side effects of      14
Paroxetine, specificity of      126
Paroxetine, studies/trials of      172 176 238
Pathophysiology      319—320
Patients, protection of      149—153
Patients, questioning of      195
Patients, recruitment strategy for      153—155 167
Paxil $\textregistered$       11
Paxipam $\textregistered$       19
PDSS      see Panic Disorder Severity Scale
Pemoline      25 86 247
Perception      65—67
Perception, disturbances of      21
Perception, tests for      66—67
Performance, deterioration of      20
Performance, mental, areas of      65—70
Periciazine      5
Perphenazme      5
Perphenazme, effects of      77—78
Personality features      91
Pertofran $\textregistered$       11
Pervitin $\textregistered$       25
PET      see positron emission tomography
Pharmaceuticals, calculating the value of      307—315
Pharmaceuticals, calculating the value of, cost-benefit analysis      308 312—313
Pharmaceuticals, calculating the value of, cost-effectiveness analysis      308—309
Pharmaceuticals, calculating the value of, cost-minimization analysis      308 312
Pharmaceuticals, calculating the value of, cost-utility analysis      308
Pharmaceuticals, development of new      125—128
Pharmaceuticals, development of new, broadband versus specific      127
Pharmaceuticals, discovery of modem      36—50
Pharmaceuticals, discovery of modem, chance      47—48
Pharmaceuticals, discovery of modem, quantitative aspects      50
Pharmaceuticals, discovery of modem, serendipity and zeitgeist      48—49
Pharmaceuticals, dose/occupancy relationships of      224
Pharmaceuticals, hypothetical mode of action      110—125
Pharmaceuticals, hypothetical mode of action, antidepressants      118—123
Pharmaceuticals, hypothetical mode of action, antipsychotics      112—118
Pharmaceuticals, hypothetical mode of action, anxiolytics      124—125
Pharmaceuticals, modern      1—26
Pharmaceuticals, modern, classification      1—3
Pharmaceuticals, modern, classification, clinical      1—2
Pharmaceuticals, modern, definition      1—3
Pharmaceuticals, modern, use of      1
Pharmaceuticals, negative image of      262
Pharmaceuticals, treatment of mental disorders, and      261—300
Pharmaco-EEG studies      see electroencephalogram
Pharmacodynamics (PD)      6 155—162 322
Pharmacodynamics (PD), PK-PD studies      155—162 186
Pharmacoeconomics and drug value      302—307
Pharmacoeconomics and quality of life      305—307
Pharmacoeconomics, analyses      308
Pharmacoeconomics, defined      301
Pharmacoeconomics, perspectives of analysis      304—305
Pharmacogenomics      140
Pharmacokinetics (PK)      6 155 322
Pharmacokinetics (PK), metabolic studies      158—162
Pharmacokinetics (PK), PK-PD studies      155—162 186
Pharmacokinetics (PK), terms and models      156—158
Pharmacokinetics (PK), trials and tolerabilitv      183—185

1 2 3 4 5 6 7 8

О проекте